UK pharma industry objects to proposed budget cap on new products

20 January 2017
nice-big-1

The trade association for the British pharmaceutical industry, the ABPI, has outlined its objections to new NICE/NHS England proposals on evaluating and funding new medicines.

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) and national healthcare provider the National Health Service (NHS) made their suggestions in a public consultation document.

The changes would see the introduction of a fast-track option for appraising technologies which are deemed to offer “exceptional value for money”.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical